Polymyositis and dermatomyositis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
*Effective measures for the secondary prevention of polymyositis and dermatomyositis include:<ref name="AggarwalRider2017">{{cite journal|last1=Aggarwal|first1=Rohit|last2=Rider|first2=Lisa G.|last3=Ruperto|first3=Nicolino|last4=Bayat|first4=Nastaran|last5=Erman|first5=Brian|last6=Feldman|first6=Brian M.|last7=Oddis|first7=Chester V.|last8=Amato|first8=Anthony A.|last9=Chinoy|first9=Hector|last10=Cooper|first10=Robert G.|last11=Dastmalchi|first11=Maryam|last12=Fiorentino|first12=David|last13=Isenberg|first13=David|last14=Katz|first14=James D.|last15=Mammen|first15=Andrew|last16=de Visser|first16=Marianne|last17=Ytterberg|first17=Steven R.|last18=Lundberg|first18=Ingrid E.|last19=Chung|first19=Lorinda|last20=Danko|first20=Katalin|last21=García-De la Torre|first21=Ignacio|last22=Song|first22=Yeong Wook|last23=Villa|first23=Luca|last24=Rinaldi|first24=Mariangela|last25=Rockette|first25=Howard|last26=Lachenbruch|first26=Peter A.|last27=Miller|first27=Frederick W.|last28=Vencovsky|first28=Jiri|title=2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheu|journal=Arthritis & Rheumatology|volume=69|issue=5|year=2017|pages=898–910|issn=23265191|doi=10.1002/art.40064}}</ref> | *Effective measures for the secondary prevention of polymyositis and dermatomyositis include:<ref name="AggarwalRider2017">{{cite journal|last1=Aggarwal|first1=Rohit|last2=Rider|first2=Lisa G.|last3=Ruperto|first3=Nicolino|last4=Bayat|first4=Nastaran|last5=Erman|first5=Brian|last6=Feldman|first6=Brian M.|last7=Oddis|first7=Chester V.|last8=Amato|first8=Anthony A.|last9=Chinoy|first9=Hector|last10=Cooper|first10=Robert G.|last11=Dastmalchi|first11=Maryam|last12=Fiorentino|first12=David|last13=Isenberg|first13=David|last14=Katz|first14=James D.|last15=Mammen|first15=Andrew|last16=de Visser|first16=Marianne|last17=Ytterberg|first17=Steven R.|last18=Lundberg|first18=Ingrid E.|last19=Chung|first19=Lorinda|last20=Danko|first20=Katalin|last21=García-De la Torre|first21=Ignacio|last22=Song|first22=Yeong Wook|last23=Villa|first23=Luca|last24=Rinaldi|first24=Mariangela|last25=Rockette|first25=Howard|last26=Lachenbruch|first26=Peter A.|last27=Miller|first27=Frederick W.|last28=Vencovsky|first28=Jiri|title=2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheu|journal=Arthritis & Rheumatology|volume=69|issue=5|year=2017|pages=898–910|issn=23265191|doi=10.1002/art.40064}}</ref> | ||
** Regular follow | ** Regular follow | ||
** Malignancy screening | ** Malignancy screening | ||
*** Effective measures for assessing malignancy in patients with polymyositis and dermatomyositis include: | *** Effective measures for assessing malignancy in patients with polymyositis and dermatomyositis include: | ||
**** Initially and annually diagnostic studies for three years including:<ref name="TiniakouMammen2015">{{cite journal|last1=Tiniakou|first1=Eleni|last2=Mammen|first2=Andrew L.|title=Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review|journal=Clinical Reviews in Allergy & Immunology|volume=52|issue=1|year=2015|pages=20–33|issn=1080-0549|doi=10.1007/s12016-015-8511-x}}</ref> | **** Initially and annually diagnostic studies for three years including:<ref name="TiniakouMammen2015">{{cite journal|last1=Tiniakou|first1=Eleni|last2=Mammen|first2=Andrew L.|title=Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review|journal=Clinical Reviews in Allergy & Immunology|volume=52|issue=1|year=2015|pages=20–33|issn=1080-0549|doi=10.1007/s12016-015-8511-x}}</ref> | ||
| Line 20: | Line 18: | ||
***** Gynecologic examination and pelvic/transvaginal ultrasonogram | ***** Gynecologic examination and pelvic/transvaginal ultrasonogram | ||
***** It is controversial to use tumor markers as a screening test for malignancy. | ***** It is controversial to use tumor markers as a screening test for malignancy. | ||
* Pulmonary protection | |||
* | |||
* Lifestyle modification including: | * Lifestyle modification including: | ||
** Physical therapy and exercise | ** Physical therapy and exercise | ||
| Line 29: | Line 26: | ||
***Limiting time outdoors | ***Limiting time outdoors | ||
***Using sunscreen | ***Using sunscreen | ||
*Prevention of medication induced complications | *Prevention of medication-induced complications | ||
** Screening for osteopenia and osteoporosis | ** Screening for osteopenia and osteoporosis | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 15:15, 18 April 2018
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis secondary prevention |
|
FDA on Polymyositis and dermatomyositis secondary prevention |
|
CDC on Polymyositis and dermatomyositis secondary prevention |
|
Polymyositis and dermatomyositis secondary prevention in the news |
|
Blogs on Polymyositis and dermatomyositis secondary prevention |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
- Effective measures for the secondary prevention of polymyositis and dermatomyositis include:[1]
- Regular follow
- Malignancy screening
- Effective measures for assessing malignancy in patients with polymyositis and dermatomyositis include:
- Initially and annually diagnostic studies for three years including:[2]
- Chest CT scan
- Abdomen CT scan
- Pelvic CT scan
- Gynecologic examination and pelvic/transvaginal ultrasonogram
- It is controversial to use tumor markers as a screening test for malignancy.
- Initially and annually diagnostic studies for three years including:[2]
- Effective measures for assessing malignancy in patients with polymyositis and dermatomyositis include:
- Pulmonary protection
- Lifestyle modification including:
- Physical therapy and exercise
- Healthy and well-balanced diet
- Watching weight
- Sun exposure protection including
- Limiting time outdoors
- Using sunscreen
- Prevention of medication-induced complications
- Screening for osteopenia and osteoporosis
References
- ↑ Aggarwal, Rohit; Rider, Lisa G.; Ruperto, Nicolino; Bayat, Nastaran; Erman, Brian; Feldman, Brian M.; Oddis, Chester V.; Amato, Anthony A.; Chinoy, Hector; Cooper, Robert G.; Dastmalchi, Maryam; Fiorentino, David; Isenberg, David; Katz, James D.; Mammen, Andrew; de Visser, Marianne; Ytterberg, Steven R.; Lundberg, Ingrid E.; Chung, Lorinda; Danko, Katalin; García-De la Torre, Ignacio; Song, Yeong Wook; Villa, Luca; Rinaldi, Mariangela; Rockette, Howard; Lachenbruch, Peter A.; Miller, Frederick W.; Vencovsky, Jiri (2017). "2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheu". Arthritis & Rheumatology. 69 (5): 898–910. doi:10.1002/art.40064. ISSN 2326-5191.
- ↑ Tiniakou, Eleni; Mammen, Andrew L. (2015). "Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review". Clinical Reviews in Allergy & Immunology. 52 (1): 20–33. doi:10.1007/s12016-015-8511-x. ISSN 1080-0549.